$9.49
7.01% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Arcturus Therapeutics Ltd Stock price

$9.49
-6.20 39.51% 1M
-15.28 61.69% 6M
-7.49 44.11% YTD
-23.26 71.03% 1Y
-21.69 69.57% 3Y
-3.51 26.98% 5Y
-30.35 76.19% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.72 7.01%
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Key metrics

Market capitalization $257.23m
Enterprise Value $-6.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.10
EV/Sales (TTM) EV/Sales -0.05
P/S ratio (TTM) P/S ratio 1.86
P/B ratio (TTM) P/B ratio 1.06
Revenue growth (TTM) Revenue growth -13.98%
Revenue (TTM) Revenue $138.39m
EBIT (operating result TTM) EBIT $-39.13m
Free Cash Flow (TTM) Free Cash Flow $-60.39m
Cash position $292.03m
EPS (TTM) EPS $-3.00
P/E forward negative
P/S forward 1.73
EV/Sales forward negative
Short interest 25.48%
Show more

Is Arcturus Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Arcturus Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

Buy
100%

Financial data from Arcturus Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
138 138
14% 14%
100%
- Direct Costs 3.52 3.52
-
3%
135 135
-
97%
- Selling and Administrative Expenses 46 46
3% 3%
33%
- Research and Development Expense 125 125
9% 9%
90%
-36 -36
786% 786%
-26%
- Depreciation and Amortization 3.52 3.52
22% 22%
3%
EBIT (Operating Income) EBIT -39 -39
466% 466%
-28%
Net Profit -81 -81
204% 204%
-58%

In millions USD.

Don't miss a Thing! We will send you all news about Arcturus Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcturus Therapeutics Ltd Stock News

Neutral
Seeking Alpha
28 days ago
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne - President and Chief Executive Officer, Director of the Board Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participa...
Neutral
Business Wire
29 days ago
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided c...
Neutral
Business Wire
30 days ago
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink's Global Heal...
More Arcturus Therapeutics Ltd News

Company Profile

Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Head office Israel
CEO Joseph Payne
Employees 176
Founded 2013
Website www.arcturusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today